An Evaluation of the Uptake and Safety of, and Adherence to Antiretroviral Treatment Among Individuals With CD4 >= 250 Cells/mm3 and HIV Virus Load >= 50,000 cp/mL

Trial Profile

An Evaluation of the Uptake and Safety of, and Adherence to Antiretroviral Treatment Among Individuals With CD4 >= 250 Cells/mm3 and HIV Virus Load >= 50,000 cp/mL

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 17 May 2013

At a glance

  • Drugs Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary) ; Efavirenz; Emtricitabine; Lamivudine; Lopinavir/ritonavir; Tenofovir disoproxil fumarate; Zidovudine
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 May 2013 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 30 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top